retatrutide weight loss results clinical trial First phase 3 data, a Triumph of Science! Triple hormone receptor agonist retatrutide

decreased smooth muscle cell proliferation reduces neointimal formation Anti-inflammatory signaling: Suppression of NF-kB, reduced macrophage infiltration into plaques, and decreased secretion of IL-6, TNF-alpha, and MCP-1 from monocytes and foam cells Atherogenic lipid reduction: Improvements in LDL cholesterol, VLDL, triglycerides, and chylomicron remnants beyond what weight loss alone would predict Blood pressure reduction: Through direct vasodilation and natriuresis, independent of weight change Epicardial and perivascular fat reduction: This fat depot exerts direct paracrine inflammatory effects on the vascular endothelium and myocardium

The benefits of the oral route are largely centered around its ease of use

doi: 10.1007/s00415-014-7632-0 55

Feel full after small meals: GLP-1 receptors affect the hypothalamus area of the brain, which triggers hunger and satiety

It inhibits the molecule called TGF-beta that pushes follicles into early regression

Idarubicin in acute leukemia: results of studies at Memorial Sloan-Kettering Cancer Center